Post Profile






P.M. Fund Roundup: Is LPL For Sale? Biotech ETFs Flounder Thanks To Illumina

Here’s some headlines for the commute home: The ripple effect of new money market reforms on M&A deals — WSJ A hedge fund is suing Theranos, accusing the embattled startup of a “series of lies” to attract investment of nearly $100 million – WSJ Biotech and health-care focused ETFs hit a slump after today’s disastrous […]
read more

share

Related Posts


The Beginning Of The End For Theranos?

Business & Finance : Zero Hedge

It started off as a bad enough day for embattled, recently notorious, biotech startup Theranos, which after a series of reports by the WSJ has found itself, and its $9 billion valuation, reeling. First, the Verge reported citing New...

Investor Sues: Theranos 'Knowingly and Repeatedly Lied'

Business & Finance : Business from Newser

Just when you thought things couldn't get worse for Theranos, this: One of its major investors has sued the company and its founder, Elizabeth Holmes, in an effort to get back its $96 million investment and then some. Partner Fund M...

A.M. Funds Roundup: Buffett Calls Trump’s Bluff; Hedge Fund Giant Cooperman Defends Himself

Business & Finance / Investing : Focus on Funds

Here are some headlines for funds and ETF investors: How did the Franklin Rising Dividends Fund (FRDPX) hit the top 1% of its group? By focusing on companies with rising dividends. – Amey Stone, Barrons.com Leon Cooperman, chairman ...

Illumina’s Pain Infects Biotech ETFs

Business & Finance / Investing : Focus on Funds

Biotech exchange-traded funds are in pain, yet again, with the iShares Nasdaq Biotechnology ETF (IBB) and the VanEck Vectors Biotech ETF (BBH) falling 2.5% and 2.3% respectively. This time, the blame falls on Illumina (ILMN). The ge...

Major Investor Sues Theranos

Technology : Tech - WSJ.com

Hedge fund accuses embattled company of a “series of lies” to attract investment of nearly $100 million.

Comments


Copyright © 2016 Regator, LLC